June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Vitreous Nonsteroidal Anti-Inflammatory Drug Levels in Vitrectomy Patients Treated with Topical Indomethacin 0.5%, Nepafenac 0.1%, and Bromfenac 0.09%
Author Affiliations & Notes
  • Raffaele Turano
    Eye Clinic, University of Brescia, Brescia, Italy
  • Andrea Russo
    Eye Clinic, University of Brescia, Brescia, Italy
  • Sara Vezzoli
    Dipartimento Specialità Medico Chirurgiche Sc. Radiol. e Sanità Pubblica, University of Brescia, Brescia, Italy
  • Francesco Morescalchi
    Eye Clinic, University of Brescia, Brescia, Italy
  • Marzia Bernini
    Dipartimento Specialità Medico Chirurgiche Sc. Radiol. e Sanità Pubblica, University of Brescia, Brescia, Italy
  • Francesco De Ferrari
    Dipartimento Specialità Medico Chirurgiche Sc. Radiol. e Sanità Pubblica, University of Brescia, Brescia, Italy
  • Ciro Costagliola
    Eye Clinic, University of Molise, Campobasso, Italy
  • Francesco Semeraro
    Eye Clinic, University of Brescia, Brescia, Italy
  • Footnotes
    Commercial Relationships Raffaele Turano, None; Andrea Russo, None; Sara Vezzoli, None; Francesco Morescalchi, None; Marzia Bernini, None; Francesco De Ferrari, None; Ciro Costagliola, None; Francesco Semeraro, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5739. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Raffaele Turano, Andrea Russo, Sara Vezzoli, Francesco Morescalchi, Marzia Bernini, Francesco De Ferrari, Ciro Costagliola, Francesco Semeraro; Vitreous Nonsteroidal Anti-Inflammatory Drug Levels in Vitrectomy Patients Treated with Topical Indomethacin 0.5%, Nepafenac 0.1%, and Bromfenac 0.09%. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5739. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine the vitreous penetration of topical indomethacin 0.5%, nepafenac 0.1%, and bromfenac 0.09% in patients previously scheduled to undergo pars plana vitrectomy.

 
Methods
 

This was a single-center, double-masked observational study of 50 eyes of 50 patients. The first 40 eyes were randomized to one of three nonsteroidal anti-inflammatory drugs (NSAID) treatment arms. Patients were instructed to take the NSAID three times a day for 7 days before pars plana vitrectomy. The next 10 eyes were untreated and served as controls. Vitreous samples were immediately stored at -20°C prior to analysis. Vitreous NSAID concentrations were quantified using a liquid chromatography mass spectroscopy system.

 
Results
 

Fifty eyes were included in the analysis. The mean (SD) vitreous concentrations were as follows: indomethacin 0.46 (0.52) ng/mL, nepafenac 0.29 (0.14) ng/mL, and bromfenac 0.30 (0.10) ng/mL. Respectively, the mean concentrations for phakic and pseudophakic eyes were 0.21 (0.28) ng/mL and 0.75 (0.62) ng/mL for indomethacin, 0.17 (0.04) ng/mL and 0.39 (0.12) ng/mL for nepafenac, and 0.21 (0.04) ng/mL and 0.36 (0.09) ng/mL for bromfenac (for all comparisons, P < 0.05).

 
Conclusions
 

All three NSAIDs penetrated into the vitreous. Vitreous levels of topical indomethacin 0.5%, nepafenac 0.1%, and bromfenac 0.09% were significantly higher in pseudophakic eyes than in phakic eyes.  

 
Mean vitreous concentrations of the study NSAIDs in patients undergoing vitrectomy treated with indomethacin 0.5%, nepafenac 0.1%, or bromfenac 0.09%. Blue columns = phakic eyes; red columns = pseudophakic eyes.
 
Mean vitreous concentrations of the study NSAIDs in patients undergoing vitrectomy treated with indomethacin 0.5%, nepafenac 0.1%, or bromfenac 0.09%. Blue columns = phakic eyes; red columns = pseudophakic eyes.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×